Brand Name | Status | Last Update |
---|---|---|
basaglar | New Drug Application | 2019-01-28 |
basaglar basaglar | Biologic Licensing Application | 2023-11-29 |
insulin glargine | Biologic Licensing Application | 2025-03-03 |
insulin glargine insulin glargine solostar | Biologic Licensing Application | 2024-01-03 |
insulin glargine solostar | Biologic Licensing Application | 2023-11-01 |
insulin glargine u-300 insulin glargine u-300 max | Biologic Licensing Application | 2024-09-10 |
lantus | Biologic Licensing Application | 2023-02-04 |
lantus lantus solostar | Biologic Licensing Application | 2024-05-23 |
lantus solostar | Biologic Licensing Application | 2023-07-22 |
rezvoglar | Biologic Licensing Application | 2024-08-09 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
type 1 diabetes mellitus | EFO_0001359 | D003922 | E10 |
hyperglycemia | — | D006943 | R73.9 |
Expiration | Code | ||
---|---|---|---|
insulin glargine, Semglee, Biocon Biologics Inc. | |||
11/15/2022 | Interchangeable excl. |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 13 | 3 | 51 | 16 | 1 | 83 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 5 | 2 | 41 | 20 | 2 | 70 |
Hyperglycemia | D006943 | — | R73.9 | — | — | 1 | 1 | — | 2 |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | 1 | — | 1 |
Infarction | D007238 | EFO_0009463 | — | — | — | — | 1 | — | 1 |
Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 7 | 2 | 10 | — | 1 | 19 |
Chronic renal insufficiency | D051436 | — | N18 | — | — | 2 | — | — | 2 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 2 | — | — | 2 |
Weight gain | D015430 | — | — | — | — | 1 | — | — | 1 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | 1 | — | — | 1 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | — | 1 |
Overweight | D050177 | — | E66.3 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 6 | — | — | — | — | 6 |
Insulin resistance | D007333 | EFO_0002614 | E88.819 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Peripheral nervous system diseases | D010523 | — | G64 | — | — | — | — | 1 | 1 |
Diabetic neuropathies | D003929 | EFO_1000783 | — | — | — | — | — | 1 | 1 |
Drug common name | Insulin glargine |
INN | insulin glargine |
Description | Insulin glargine recombinant |
Classification | Protein |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | 4IYD, 4IYF, 5VIZ |
CAS-ID | 160337-95-1 |
RxCUI | 274783 |
ChEMBL ID | CHEMBL1201497 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00047 |
UNII ID | 2ZM8CX04RZ (ChemIDplus, GSRS) |